THE DECISION ON THE AMENDMENT OF THE PRICING DECISION OF MEDICINAL PRODUCTS FOR HUMAN USE
- Jul 8, 2022
- 1 min read
The Decision on the Amendment of the Pricing Decision of Medicinal Products for Human Use (“Decision”) has been published in the Official Gazette dated 8 July 2022 and entered into force. Increases and changes introduced by the Decision are explained below.
Warehouse and pharmacist profit rates to be applied for the determination of retail sale prices of the products have been determined as follows:
Euro value used for pricing of the products has been increased by 25% to be effective as of 9 July 2022.
The value scales of the products have been updated in line with the increase in the Euro value and have been determined as 27.13 TRY for the price-protected products and 14.18 TRY for other products.
To be applied following the increase in Euro value, prices of the products without source tracking have been decided to be increased by below rates:
Besides, mentioned increases will be applied to price protected products up to a maximum of 27.13 TRY (including 27.13 TRY) and to a maximum of 14.18 TRY (not including 14.18 TRY) for other products.
The Decision has entered into force as of its publication date.
